ARTICLE | Financial News

Hookipa raises €50M series C

December 14, 2017 2:09 AM UTC

Hookipa Biotech AG (Vienna, Austria) raised €50 million ($59.4 million) in a series C round led by an undisclosed U.S. public investment fund specializing in life sciences. Fellow new investors HBM Partners, Hillhouse Capital, Sirona Capital and Gilead Sciences Inc. (NASDAQ:GILD) also participated, as did existing investors Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.

In mid-2018, Hookipa expects to start a Phase II trial of HB-101 to prevent cytomegalovirus (CMV) infection, with data expected in 2019. HB-101 is a bivalent vaccine against CMV that uses Hookipa’s Vaxwave vector -- a replication-deficient arenavirus -- to express CMV phosphoprotein 65 (pp65; UL83) and truncated CMV glycoprotein B...

BCIQ Company Profiles

Hookipa Pharma Inc.